A recent study from the University of Maryland School of Medicine indicates that weight-loss drugs, specifically GLP-1 receptor agonists like semaglutide and tirzepatide, could prevent thousands of knee replacement surgeries each year. Osteoarthritis, particularly knee arthritis, affects millions globally, with significant numbers requiring surgical intervention. The research analyzed data from 6.8 million adults diagnosed with knee osteoarthritis and found that using these medications for three years could reduce the need for surgery by nearly 5 percentage points. If all eligible patients in the US utilized these drugs, it could lead to approximately 14,400 fewer surgeries annually. However, experts, including consultant knee surgeon Mark Bowditch, urge caution, noting that these medications are not approved for osteoarthritis treatment and should only be used in clinical trials. Prof Lucy Donaldson from Arthritis UK highlighted the importance of maintaining a healthy weight in managing osteoarthritis symptoms.